[
Atypical response
Dissociated response
Immunotherapy
PET/CT
Pseudoprogression
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
19 Jun 2024
19 Jun 2024
Historique:
received:
08
03
2024
accepted:
05
06
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
19
6
2024
Statut:
aheadofprint
Résumé
To determine the long-term prognosis of immune-related response profiles (pseudoprogression and dissociated response), not covered by conventional PERCIST criteria, in patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs). 109 patients were prospectively included and underwent [ Median follow-up was 21 months. At PET [ HDH F20230309081206. Registered 20 April 2023. Retrospectively registered.
Identifiants
pubmed: 38896129
doi: 10.1007/s00259-024-06794-8
pii: 10.1007/s00259-024-06794-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Zhang Y, Luo G, Etxeberria J, Hao Y. Global patterns and trends in lung cancer incidence: A population-based study. J Thorac Oncol. 2021;16:933–44.
doi: 10.1016/j.jtho.2021.01.1626
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.
doi: 10.1056/NEJMoa1507643
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–65.
doi: 10.1016/S0140-6736(16)32517-X
Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 2016;387:1540–50.
doi: 10.1016/S0140-6736(15)01281-7
Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35:3924–33.
doi: 10.1200/JCO.2017.74.3062
Ramos-Esquivel A, van der Laat A, Rojas-Vigott R, Juárez M, Corrales-Rodríguez L. Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. ESMO Open. 2017;2: e000236.
doi: 10.1136/esmoopen-2017-000236
Aide N, Hicks RJ, Le Tourneau C, et al. FDG PET/CT for assessing tumour response to immunotherapy. Eur J Nucl Med Mol Imaging. 2019;46:238–50.
doi: 10.1007/s00259-018-4171-4
Sheikhbahaei S, Verde F, Hales RK, et al. Imaging in therapy response assessment and surveillance of lung cancer: Evidenced-based review with focus on the utility of 18F-FDG PET/CT. Clin Lung Cancer. 2020;21:485–97.
doi: 10.1016/j.cllc.2020.06.020
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
doi: 10.1016/j.ejca.2008.10.026
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-S150.
doi: 10.2967/jnumed.108.057307
Sachpekidis C, Anwar H, Winkler J, et al. The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2018;45:1289–96.
doi: 10.1007/s00259-018-3972-9
Hughes DJ, Subesinghe M, Taylor B, et al. 18F FDG PET/CT and novel molecular imaging for directing immunotherapy in cancer. Radiology. 2022;304:246–64.
doi: 10.1148/radiol.212481
Goldfarb L, Duchemann B, Chouahnia K, et al. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res. 2019;9:8.
doi: 10.1186/s13550-019-0473-1
Ito K, Teng R, Schöder H, et al. 18F-FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma. J Nucl Med. 2019;60:335–41.
doi: 10.2967/jnumed.118.213652
Anwar H, Sachpekidis C, Winkler J, et al. Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45:376–83.
doi: 10.1007/s00259-017-3870-6
Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, et al. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging. 2022;49:2323–41.
doi: 10.1007/s00259-022-05780-2
Lopci E, Aide N, Dimitrakopoulou-Strauss A, et al. Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors. Cancer Imaging. 2022;22:73.
doi: 10.1186/s40644-022-00512-z
Borcoman E, Kanjanapan Y, Champiat S, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30:385–96.
doi: 10.1093/annonc/mdz003
Humbert O, Chardin D. Dissociated response in metastatic cancer: An atypical pattern brought into the spotlight with immunotherapy. Front Oncol. 2020;10:1792.
doi: 10.3389/fonc.2020.566297
Guan Y, Feng D, Yin B, Li K, Wang J. Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade. Ther Adv Med Oncol. 2022;14:17588359221096876.
doi: 10.1177/17588359221096877
Cho SY, Lipson EJ, Im H-J, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med. 2017;58:1421–8.
doi: 10.2967/jnumed.116.188839
Kaira K, Higuchi T, Naruse I, et al. Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC. Eur J Nucl Med Mol Imaging. 2018;45:56–66.
doi: 10.1007/s00259-017-3806-1
Rocha P, Hardy-Werbin M, Naranjo D, et al. CD103+CD8+ lymphocytes characterize the immune infiltration in a case with pseudoprogression in squamous NSCLC. J Thorac Oncol. 2018;13:e193–6.
doi: 10.1016/j.jtho.2018.05.008
Hodi FS, Hwu W-J, Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510–7.
doi: 10.1200/JCO.2015.64.0391
Humbert O, Cadour N, Paquet M, et al. 18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging. 2020;47:1158–67.
doi: 10.1007/s00259-019-04573-4
Rossi G, Bauckneht M, Genova C, et al. Comparison between 18F-FDG PET-based and CT-based criteria in non-small cell lung cancer patients treated with nivolumab. J Nucl Med. 2020;61:990–8.
doi: 10.2967/jnumed.119.233056
Queirolo P, Spagnolo F. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. Cancer Treat Rev. 2017;59:71–8.
doi: 10.1016/j.ctrv.2017.07.002
Park HJ, Kim KW, Pyo J, et al. Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: A systematic review and meta-analysis. Radiology. 2020;297:87–96.
doi: 10.1148/radiol.2020200443
Chen M-Y, Zeng Y-C. Pseudoprogression in lung cancer patients treated with immunotherapy. Crit Rev Oncol Hematol. 2022;169:103531.
doi: 10.1016/j.critrevonc.2021.103531
Huyge V, Garcia C, Alexiou J, et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol). 2010;22:818–27.
doi: 10.1016/j.clon.2010.05.021
Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018;88:38–47.
doi: 10.1016/j.ejca.2017.10.017
Tozuka T, Kitazono S, Sakamoto H, et al. Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors. BMC Cancer. 2020;20:207.
doi: 10.1186/s12885-020-6704-z
Bernard-Tessier A, Baldini C, Castanon E, et al. Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunol Immunother. 2021;70:221–32.
doi: 10.1007/s00262-020-02647-z
Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals Oncol. 2018;29:192–237.
doi: 10.1093/annonc/mdy275
Martin-Romano P, Castanon E, Ammari S, et al. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. Cancer Med. 2020;9:2643–52.
doi: 10.1002/cam4.2797
Fujimoto D, Yoshioka H, Kataoka Y, et al. Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy. J Thorac Oncol. 2019;14:468–74.
doi: 10.1016/j.jtho.2018.10.167
Sato Y, Morimoto T, Hara S, et al. Dissociated response and clinical benefit in patients treated with nivolumab monotherapy. Invest New Drugs. 2021;39:1170–8.
doi: 10.1007/s10637-021-01077-7
Anderson TM, Chang BH, Huang AC, et al. FDG PET/CT Imaging 1 week after a single dose of pembrolizumab predicts treatment response in patients with advanced melanoma. Clin Cancer Res. 2024;OF1–10.
Gonugunta AS, von Itzstein MS, Gerber DE. Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report. J Med Case Rep. 2022;16:289.
doi: 10.1186/s13256-022-03485-6
Humbert O, Bauckneht M, Gal J, et al. Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2022;49:3878–91.
doi: 10.1007/s00259-022-05788-8